FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379337997> ?p ?o ?g. }

• W4379337997 endingPage "10031" @default.
• W4379337997 startingPage "10031" @default.
• W4379337997 abstract "10031 Background: Survival for pediatric B-cell lymphomas (BCL) exceeds 90% with modern regimens, however outcomes remain poor for patients with relapsed or refractory (R/R) disease. Tisagenlecleucel is a CD19-directed CAR T-cell therapy (CART) that is FDA approved for adults with R/R BCL. No data exists for use of tisagenlecleucel in R/R pediatric BCL. Methods: We surveyed 48 sites in the Pediatric Real-World CAR Consortium to retrospectively describe use and outcomes of tisagenlecleucel for pediatric patients with R/R BCL. This cohort included 10 patients from 7 centers aged ≤25 years who were infused between 2019-2022 and were ≥3 months from CART. We aimed to describe response rates, as determined by each institution based on positron emission tomography, bone marrow evaluation, and/or cerebrospinal fluid (CSF) studies, along with toxicity and outcomes in this population. Results: Ten patients received CART with a median age at infusion of 19 (range, 7-24) years. Five patients had B-lymphoblastic lymphoma (B-LLy), 2 had primary mediastinal BCL, and 1 each had Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disorder related DLBCL. Five patients had primary refractory disease, and 5 were in ≥2 nd relapse. Three had received prior hematopoietic stem cell transplant (HSCT). Two had CSF involvement, and 1 had central nervous system parenchymal disease at time of infusion. CART was well tolerated with 1 patient experiencing grade 3 cytokine release syndrome and 2 patients experiencing neurotoxicity (grade 2 n = 1, grade 3 n = 1), both of whom had CSF involvement at time of CART infusion. Best overall response was complete response (CR) for 6, partial response (PR) for 2, and refractory disease for 2. Two patients, both with B-LLy, underwent allogeneic HSCT while in CART-mediated CR with B-cell aplasia. Both patients with PR (1 DLBCL, 1 Burkitt) subsequently relapsed with CD19-negative disease; the patient with DLBCL subsequently achieved CR with salvage immuno-chemotherapy and HSCT. All 6 CR patients remain in remission at a median time to follow-up of 31 (range, 14-47) months. Conclusions: This multicenter case series of CD19-directed CART for R/R pediatric BCL suggests that tisagenlecleucel may be safe and active in this population with all CR patients currently in sustained remission. Larger studies are needed to understand how best to incorporate CART into treatment for R/R pediatric BCL. [Table: see text]" @default.
• W4379337997 created "2023-06-05" @default.
• W4379337997 creator A5001676247 @default.
• W4379337997 creator A5013942819 @default.
• W4379337997 creator A5017731707 @default.
• W4379337997 creator A5032104588 @default.
• W4379337997 creator A5032120009 @default.
• W4379337997 creator A5036696622 @default.
• W4379337997 creator A5051925691 @default.
• W4379337997 creator A5054397260 @default.
• W4379337997 creator A5056146847 @default.
• W4379337997 creator A5061884188 @default.
• W4379337997 creator A5062207406 @default.
• W4379337997 creator A5075107011 @default.
• W4379337997 creator A5087189305 @default.
• W4379337997 date "2023-06-01" @default.
• W4379337997 modified "2023-10-16" @default.
• W4379337997 title "Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas." @default.
• W4379337997 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.10031" @default.
• W4379337997 hasPublicationYear "2023" @default.
• W4379337997 type Work @default.
• W4379337997 citedByCount "0" @default.
• W4379337997 crossrefType "journal-article" @default.
• W4379337997 hasAuthorship W4379337997A5001676247 @default.
• W4379337997 hasAuthorship W4379337997A5013942819 @default.
• W4379337997 hasAuthorship W4379337997A5017731707 @default.
• W4379337997 hasAuthorship W4379337997A5032104588 @default.
• W4379337997 hasAuthorship W4379337997A5032120009 @default.
• W4379337997 hasAuthorship W4379337997A5036696622 @default.
• W4379337997 hasAuthorship W4379337997A5051925691 @default.
• W4379337997 hasAuthorship W4379337997A5054397260 @default.
• W4379337997 hasAuthorship W4379337997A5056146847 @default.
• W4379337997 hasAuthorship W4379337997A5061884188 @default.
• W4379337997 hasAuthorship W4379337997A5062207406 @default.
• W4379337997 hasAuthorship W4379337997A5075107011 @default.
• W4379337997 hasAuthorship W4379337997A5087189305 @default.
• W4379337997 hasConcept C121332964 @default.
• W4379337997 hasConcept C121608353 @default.
• W4379337997 hasConcept C126322002 @default.
• W4379337997 hasConcept C142424586 @default.
• W4379337997 hasConcept C143998085 @default.
• W4379337997 hasConcept C203014093 @default.
• W4379337997 hasConcept C2776090121 @default.
• W4379337997 hasConcept C2776694085 @default.
• W4379337997 hasConcept C2777408962 @default.
• W4379337997 hasConcept C2777478502 @default.
• W4379337997 hasConcept C2777701055 @default.
• W4379337997 hasConcept C2778020697 @default.
• W4379337997 hasConcept C2778559949 @default.
• W4379337997 hasConcept C2778957590 @default.
• W4379337997 hasConcept C2779338263 @default.
• W4379337997 hasConcept C2780775027 @default.
• W4379337997 hasConcept C2780850621 @default.
• W4379337997 hasConcept C2908647359 @default.
• W4379337997 hasConcept C2911091166 @default.
• W4379337997 hasConcept C3017910909 @default.
• W4379337997 hasConcept C3875195 @default.
• W4379337997 hasConcept C71924100 @default.
• W4379337997 hasConcept C87355193 @default.
• W4379337997 hasConcept C8891405 @default.
• W4379337997 hasConcept C99454951 @default.
• W4379337997 hasConceptScore W4379337997C121332964 @default.
• W4379337997 hasConceptScore W4379337997C121608353 @default.
• W4379337997 hasConceptScore W4379337997C126322002 @default.
• W4379337997 hasConceptScore W4379337997C142424586 @default.
• W4379337997 hasConceptScore W4379337997C143998085 @default.
• W4379337997 hasConceptScore W4379337997C203014093 @default.
• W4379337997 hasConceptScore W4379337997C2776090121 @default.
• W4379337997 hasConceptScore W4379337997C2776694085 @default.
• W4379337997 hasConceptScore W4379337997C2777408962 @default.
• W4379337997 hasConceptScore W4379337997C2777478502 @default.
• W4379337997 hasConceptScore W4379337997C2777701055 @default.
• W4379337997 hasConceptScore W4379337997C2778020697 @default.
• W4379337997 hasConceptScore W4379337997C2778559949 @default.
• W4379337997 hasConceptScore W4379337997C2778957590 @default.
• W4379337997 hasConceptScore W4379337997C2779338263 @default.
• W4379337997 hasConceptScore W4379337997C2780775027 @default.
• W4379337997 hasConceptScore W4379337997C2780850621 @default.
• W4379337997 hasConceptScore W4379337997C2908647359 @default.
• W4379337997 hasConceptScore W4379337997C2911091166 @default.
• W4379337997 hasConceptScore W4379337997C3017910909 @default.
• W4379337997 hasConceptScore W4379337997C3875195 @default.
• W4379337997 hasConceptScore W4379337997C71924100 @default.
• W4379337997 hasConceptScore W4379337997C87355193 @default.
• W4379337997 hasConceptScore W4379337997C8891405 @default.
• W4379337997 hasConceptScore W4379337997C99454951 @default.
• W4379337997 hasIssue "16_suppl" @default.
• W4379337997 hasLocation W43793379971 @default.
• W4379337997 hasOpenAccess W4379337997 @default.
• W4379337997 hasPrimaryLocation W43793379971 @default.
• W4379337997 hasRelatedWork W1969631111 @default.
• W4379337997 hasRelatedWork W2890700631 @default.
• W4379337997 hasRelatedWork W2930076345 @default.
• W4379337997 hasRelatedWork W2971349430 @default.
• W4379337997 hasRelatedWork W3030846676 @default.
• W4379337997 hasRelatedWork W3040347271 @default.
• W4379337997 hasRelatedWork W3095855647 @default.
• W4379337997 hasRelatedWork W3115928935 @default.

• next